Kimia Farma Past Earnings Performance
Past criteria checks 0/6
Kimia Farma's earnings have been declining at an average annual rate of -79.1%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 0.4% per year.
Key information
-79.1%
Earnings growth rate
-79.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 20.4% |
| Revenue growth rate | 0.4% |
| Return on equity | -38.9% |
| Net Margin | -16.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kimia Farma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10,114,020 | -1,710,594 | 3,799,288 | 76,274 |
| 30 Jun 24 | 10,232,290 | -1,652,563 | 3,896,107 | 85,970 |
| 31 Mar 24 | 10,197,139 | -1,550,660 | 3,917,662 | 92,850 |
| 31 Dec 23 | 9,965,033 | -1,466,125 | 3,888,022 | 97,042 |
| 30 Sep 23 | 9,814,252 | -171,442 | 3,054,950 | 45,949 |
| 30 Jun 23 | 9,753,970 | -10,237 | 2,994,674 | 43,893 |
| 31 Mar 23 | 9,275,845 | -198,984 | 2,975,992 | 43,536 |
| 31 Dec 22 | 9,232,676 | -175,017 | 2,889,203 | 46,365 |
| 30 Sep 22 | 10,497,735 | -180,600 | 2,777,817 | 51,316 |
| 30 Jun 22 | 11,724,246 | 39,551 | 2,865,793 | 47,096 |
| 31 Mar 22 | 12,817,935 | 290,748 | 2,856,371 | 44,661 |
| 31 Dec 21 | 12,857,627 | 302,274 | 2,860,390 | 41,348 |
| 30 Sep 21 | 12,454,077 | 282,376 | 3,055,618 | 19,880 |
| 30 Jun 21 | 10,876,894 | 26,664 | 2,816,085 | 19,717 |
| 31 Mar 21 | 9,904,089 | 8,770 | 2,779,877 | 15,678 |
| 31 Dec 20 | 10,006,173 | 17,639 | 2,791,532 | 15,527 |
| 30 Sep 20 | 9,567,319 | -17,359 | 2,702,280 | 25,488 |
| 30 Jun 20 | 9,563,520 | -11,902 | 2,740,519 | 21,160 |
| 31 Mar 20 | 9,987,987 | -7,192 | 2,852,496 | 20,919 |
| 31 Dec 19 | 9,400,535 | -12,724 | 2,734,944 | 15,324 |
| 30 Sep 19 | 9,338,053 | 307,947 | 2,527,679 | 25,015 |
| 30 Jun 19 | 9,174,701 | 387,400 | 2,444,690 | 15,650 |
| 31 Mar 19 | 8,783,887 | 474,990 | 2,329,205 | 9,578 |
| 31 Dec 18 | 8,459,247 | 491,566 | 2,202,455 | 14,417 |
| 30 Sep 18 | 7,825,603 | 360,271 | 2,056,686 | 1,174 |
| 30 Jun 18 | 7,301,293 | 383,635 | 1,865,250 | 9,934 |
| 31 Mar 18 | 6,419,703 | 334,804 | 1,641,605 | 14,854 |
| 31 Dec 17 | 6,127,479 | 326,786 | 1,555,146 | 8,714 |
| 30 Sep 17 | 6,145,736 | 285,555 | 1,440,329 | 22,726 |
| 30 Jun 17 | 5,957,153 | 268,890 | 1,353,364 | 25,174 |
| 31 Mar 17 | 5,870,811 | 254,615 | 1,241,024 | 27,084 |
| 31 Dec 16 | 5,811,503 | 267,414 | 1,218,150 | 29,149 |
| 30 Sep 16 | 5,353,790 | 271,671 | 1,161,794 | 25,227 |
| 30 Jun 16 | 5,241,479 | 277,575 | 1,151,560 | 19,604 |
| 31 Mar 16 | 4,984,012 | 259,512 | 1,061,877 | 20,395 |
| 31 Dec 15 | 4,860,371 | 261,426 | 1,032,487 | 19,134 |
| 30 Sep 15 | 4,917,458 | 275,686 | 965,922 | 16,994 |
| 30 Jun 15 | 4,730,427 | 262,798 | 916,848 | 18,425 |
| 31 Mar 15 | 4,669,013 | 276,467 | 897,852 | 15,120 |
| 31 Dec 14 | 4,521,024 | 255,931 | 875,033 | 15,270 |
| 30 Sep 14 | 4,609,869 | 236,927 | 886,781 | 16,446 |
| 30 Jun 14 | 4,506,515 | 242,356 | 896,792 | 17,200 |
| 31 Mar 14 | 4,415,611 | 213,478 | 893,440 | 18,772 |
| 31 Dec 13 | 4,348,074 | 214,549 | 896,287 | 17,254 |
Quality Earnings: KAEF is currently unprofitable.
Growing Profit Margin: KAEF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KAEF is unprofitable, and losses have increased over the past 5 years at a rate of 79.1% per year.
Accelerating Growth: Unable to compare KAEF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KAEF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).
Return on Equity
High ROE: KAEF has a negative Return on Equity (-38.93%), as it is currently unprofitable.